Servier’s decision to exit a Parkinson’s disease pact has triggered belt tightening at French biotech Oncodesign Precision Medicine. | Servier’s decision to exit a Parkinson’s disease pact has ...

Agios hit a setback for Tibsovo in Europe this year however after the EMA rejected the marketing application for the drug. Servier is paying $1.8 billion upfront for the oncology assets, with the ...

Now, Servier says it has data from a phase 3 trial in the previously-untreated group that could allow it to have another go at European approval, and also support the drug's use as part of a first ...

the biotech has licensed the RAF inhibitor to Servier for $70 million upfront and up to $710 million in milestones. In October, Black Diamond concluded its attempt to push two cancer drugs through ...

As such, Servier is focusing on a limited number of neurodegenerative diseases where accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine.

This is one woman’s campaign against a drug maker that sold harmful products ... was going to spend my life caring for the victims of Servier, battling to make this poison recognized as such ...

Servier will lead the development activities ... Also Read: Black Diamond Therapeutics’ Lead Drug Candidate Shows Initial Anti-Tumor Activity In Certain Type Of Lung Cancer Resistant To ...

“Servier’s commitment to innovation and deep ... the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France, Eastern Europe ...